OncoTartis
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
640 Ellicott St Ste 480, Buffalo, New Yo...Phone Number
(716) 858-3055Website
www.oncotartis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About OncoTartis
OncoTartis, Inc. is a private biotechnology company focused on developing novel anti-cancer drugs targeting tissue-specific vulnerabilities in cancers such as breast, prostate, ovarian, melanoma, and hematological malignancies. Founded in 2011, the company leverages a proprietary drug discovery approach known as TARTIS to create small molecules, including their leading product OT-82, a NAMPT inhibitor aimed at treating hematological malignancies. The pipeline for OT-82 has progressed to a Phase 1/2a clinical study initiated in 2019 across five US centers. OncoTartis primarily targets oncologists and healthcare professionals involved in the treatment of specific cancer types.Explore more
OncoTartis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OncoTartis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on OncoTartis recently announced quarterly report
Funding: Get notified immidiatlly once OncoTartis has new funding data
Website visits: Recent activity has been detected on your website
Click to see if OncoTartis had a recent Job posting/layoffs
Check out if OncoTartis is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if OncoTartis has recently received funding, and reach out quickly before it becomes old news!
OncoTartis, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at OncoTartis
Product Launch: Get notified when OncoTartis launches new products
Recommended Actions
Reach out to Masked Content who joined OncoTartis as Masked Content
Find 2 more new buyers
Compare Similar Companies to OncoTartis
Compare insights from companies similar to OncoTartis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OncoTartis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OncoTartis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OncoTartis.
OncoTartis financials insights
Gather financial insights about OncoTartis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Unspecified
$6M
2021
Debt
$57K
OncoTartis Tech Stack
A closer look at the technologies used by OncoTartis
OncoTartis News & Media
International Research Collaboration Reveals Promising Drug Candidate for Treatment of Blood Cancers
An international research collaboration between the United States and Australia has revealed a promising new drug that could treat high-risk l ...International Research Collaboration Reveals Promising Drug Candidate for Treatment of Blood Cancers
An international research collaboration between the United States and Australia has revealed a promising new drug that could treat high-risk leukemia.OncoTartis nets $6 mln
Buffalo, New York-based OncoTartis, a developer of anti-cancer drugs, has secured $6 million in funding. The investors included Norma Investments representing Roman Abramovich and Pharmstandard International S.A.OncoTartis Closes $6M Financing Round
OncoTartis, Inc., a Buffalo, NY-based biotechnology company developing a novel category of anti-cancer drugs, closed a $6m financing round. Backers included Norma Investments, representing businessman Roman Abramovich, and Pharmstandard International S.A. The company intends to use the funds for support the Phase 1 clinical trial of its lead drug candidate OT-82. Established in 2011 and […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OncoTartis
Sign Up For FreeTo access detailed company insights
OncoTartis, Inc. is a private biotechnology company focused on developing novel anti-cancer drugs targeting tissue-specific vulnerabilities in cancers such as breast, prostate, ovarian, melanoma, and hematological malignancies. Founded in 2011, the company leverages a proprietary drug discovery approach known as TARTIS to create small molecules, in... Read More
